LIA Stock Overview A medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Add notePrice History & Performance
Summary of share price highs, lows and changes for LivaNova Historical stock prices Current Share Price US$45.60 52 Week High US$59.00 52 Week Low US$39.00 Beta 0.99 1 Month Change -5.39% 3 Month Change 0.44% 1 Year Change -1.72% 3 Year Change -38.79% 5 Year Change -31.94% Change since IPO 163.58%
Recent News & Updates
LivaNova PLC Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints Nov 12
Third quarter 2024 earnings released: EPS: US$0.61 (vs US$0.14 loss in 3Q 2023) Nov 01
High number of new directors Nov 01
LivaNova PLC Appoints Susan Podlogar as New Director Oct 08
LivaNova PLC to Report Q3, 2024 Results on Oct 30, 2024 Sep 27
Trui Hebbelinck Leaves Position of LivaNova Plc's Chief Human Resources Officer Sep 10 See more updates
LivaNova PLC Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints Nov 12
Third quarter 2024 earnings released: EPS: US$0.61 (vs US$0.14 loss in 3Q 2023) Nov 01
High number of new directors Nov 01
LivaNova PLC Appoints Susan Podlogar as New Director Oct 08
LivaNova PLC to Report Q3, 2024 Results on Oct 30, 2024 Sep 27
Trui Hebbelinck Leaves Position of LivaNova Plc's Chief Human Resources Officer Sep 10
Second quarter 2024 earnings released: EPS: US$0.30 (vs US$0.021 in 2Q 2023) Aug 01
LivaNova PLC Provides Earnings Guidance for the Year 2024 Jul 31
LivaNova PLC to Report Q2, 2024 Results on Jul 31, 2024 Jun 19
Daniel Jeffrey Moore Resigns as Director of LivaNova PLC Jun 14
LivaNova PLC Provides Update on Recover Clinical Study Evaluating Vns Therapy for Treatment-Resistant Depression in Unipolar Patients Jun 08
LivaNova PLC Provides Earnings Guidance for the Full-Year 2024 May 03
First quarter 2024 earnings released: US$0.78 loss per share (vs US$0.14 profit in 1Q 2023) May 02
LivaNova PLC Announces Ahmet Tezel, Ph.D., as Chief Innovation Officer Apr 30
LivaNova PLC, Annual General Meeting, Jun 11, 2024 Apr 28
LivaNova PLC to Report Q1, 2024 Results on May 01, 2024 Mar 22
LivaNova PLC Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea Mar 20
Full year 2023 earnings released: EPS: US$0.33 (vs US$1.61 loss in FY 2022) Feb 22 Livanova plc Announces Impairment Charges for the Three Month Ended December 31, 2023 LivaNova PLC Announces CEO Changes, Effective on March 1, 2024
LivaNova PLC to Report Q4, 2023 Results on Feb 21, 2024 Jan 05
New minor risk - Earnings quality Nov 03
Livanova plc Provides Revenue Guidance for the Full-Year 2023 Nov 02
Third quarter 2023 earnings released: US$0.14 loss per share (vs US$2.01 loss in 3Q 2022) Nov 02
LivaNova PLC Announces Board Changes Oct 07
Marco Dolci to Retire as President of Cardiopulmonary Business Unit of LivaNova PLC on December 31, 2023 Sep 22
LivaNova PLC to Report Q3, 2023 Results on Nov 01, 2023 Sep 21
LivaNova Unveils Essenz In-Line Blood Monitor with U.S. FDA 510(k) Clearance and CE Mark Aug 31
LivaNova PLC Provides Financial Guidance for the Full Year 2023 Jul 27
Second quarter 2023 earnings released: EPS: US$0.022 (vs US$0.31 in 2Q 2022) Jul 27
LivaNova PLC to Report Q2, 2023 Results on Jul 26, 2023 Jun 15
LivaNova PLC Announces 150th Bipolar Depression Patient Randomized in Recover Clinical Study Jun 14
LivaNova PLC Provides Earnings Guidance for the Full Year 2023 May 04
First quarter 2023 earnings released: EPS: US$0.14 (vs US$0.056 in 1Q 2022) May 03
Full year 2022 earnings released: US$1.61 loss per share (vs US$2.68 loss in FY 2021) Feb 22
LivaNova PLC Initiates Limited Commercial Release in Europe of the Essenz Perfusion System for Cardiopulmonary Bypass Procedures Feb 09
LivaNova Launches SenTiva DUO Feb 03
LivaNova PLC to Report Q4, 2022 Results on Feb 22, 2023 Jan 19
Forecast breakeven date pushed back to 2023 Nov 16
Forecast breakeven date pushed back to 2023 Nov 08
Third quarter 2022 earnings released: US$2.01 loss per share (vs US$0.82 loss in 3Q 2021) Nov 03 LivaNova PLC Announces Management Changes
LivaNova PLC to Report Q3, 2022 Results on Nov 02, 2022 Sep 22
LivaNova PLC Appoints Brooke Story as New Director Sep 16
Second quarter 2022 earnings released: EPS: US$0.31 (vs US$1.13 loss in 2Q 2021) Aug 04
LivaNova PLC Provides Earnings Guidance for the Full Year 2022 Aug 04
LivaNova PLC to Report Q2, 2022 Results on Aug 03, 2022 Jun 23
Now 21% undervalued after recent price drop Jun 18 LivaNova PLC Announces Executive Changes
LivaNova PLC (NasdaqGS : LIVN) acquired additional 97% majority stake in ALung Technologies, Inc. May 06
First quarter 2022 earnings released: EPS: US$0.056 (vs US$0.61 loss in 1Q 2021) May 05 LivaNova PLC Provides Earnings Guidance for the Full-Year 2022
LivaNova PLC, Annual General Meeting, Jun 13, 2022 May 02
LivaNova PLC Initiates Targeted Commercial Launch of the Essenz Patient Monitor for Cardiopulmonary Bypass Procedures Apr 09
LivaNova Announces First Patient Implanted in OSPREY Clinical Study for Patients Coping with Obstructive Sleep Apnea Feb 25
Full year 2021 earnings: Revenues and EPS in line with analyst expectations Feb 24
Independent Non-Executive Director recently sold €233k worth of stock Nov 13
Third quarter 2021 earnings released: US$0.82 loss per share (vs US$0.30 loss in 3Q 2020) Nov 04
Forecast to breakeven in 2022 Sep 23
LivaNova PLC has completed a Follow-on Equity Offering in the amount of $300.00003 million. Aug 05
Second quarter 2021 earnings released: US$1.13 loss per share (vs US$1.81 loss in 2Q 2020) Jul 29
LivaNova PLC Receives FDA Approval for Clinical Study to Evaluate the Aura6000 System to Treat Obstructive Sleep Apnea Jun 16
Independent Non-Executive Director Hugh Morrison has left the company Jun 15
Head of Global Operations and R&D recently sold €493k worth of stock May 21
First quarter 2021 earnings released: US$0.61 loss per share (vs US$0.80 profit in 1Q 2020) May 01
LivaNova PLC Reaffirms Sales Guidance for 2021 Apr 29
LivaNova PLC and Verily Announce First Patient Enrolled in Study to Evaluate Treatment Effectiveness for Patients Living with Depression Apr 27
Full year 2020 earnings released: US$7.07 loss per share (vs US$3.22 loss in FY 2019) Feb 25
Revenue misses expectations Feb 25
New 90-day high: €60.00 Feb 25
New 90-day high: €57.50 Feb 10
LivaNova PLC to Report Q4, 2020 Results on Feb 24, 2021 Jan 21
Medistim ASA Partners with Livanova PLC as Their New Distributor for India Jan 06
New 90-day high: €51.00 Dec 12
Gyrus Capital S.A. entered into an agreement to acquire Sorin Group Italia S.r.l. and LivaNova Site Management S.r.l and LivaNova Canada Corp and Heart Valve Business from LivaNova PLC for enterprise value of €60 million. Dec 04
Third quarter earnings released Oct 30
Third-quarter earnings released: Revenue beats expectations Oct 30
LivaNova PLC Announces Executive Changes Oct 30
LivaNova PLC Announces New Data from the Perceval® Sutureless Implant Versus Standard-Aortic Valve Replacement (PERSIST-AVR) Clinical Study and the Sorin Universal Registry on Aortic Valve Replacement Oct 13
LivaNova PLC to Report Q3, 2020 Results on Oct 29, 2020 Sep 30
New 90-day low: €36.60 Sep 22
New 90-day low - €38.20 Sep 05
New 90-day low - €39.40 Aug 03 LivaNova PLC to Report Q2, 2020 Results on Jul 29, 2020 Jun 30
Shareholder Returns LIA DE Medical Equipment DE Market 7D -6.6% -3.2% -2.0% 1Y -1.7% -8.4% 6.8%
See full shareholder returns
Return vs Market: LIA underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is LIA's price volatile compared to industry and market? LIA volatility LIA Average Weekly Movement 5.9% Medical Equipment Industry Average Movement 6.6% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.4% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: LIA has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: LIA's weekly volatility (6%) has been stable over the past year.
About the Company LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Show more LivaNova PLC Fundamentals Summary How do LivaNova's earnings and revenue compare to its market cap? LIA fundamental statistics Market cap €2.48b Earnings (TTM ) €22.76m Revenue (TTM ) €1.19b
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) LIA income statement (TTM ) Revenue US$1.24b Cost of Revenue US$396.25m Gross Profit US$845.49m Other Expenses US$821.80m Earnings US$23.68m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 18:45 End of Day Share Price 2024/12/23 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources LivaNova PLC is covered by 30 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution David Rescott Baird Michael Polark Baird Matt Miksic Barclays
Show 27 more analysts